The mission is a part of the Cambridge Crossing innovation hub.
DivcoWest has topped off 441 Morgan Ave., the corporate’s fifth life science constructing inside its Cambridge Crossing mixed-use growth. John Moriarty & Associates is the development supervisor, whereas Ennead and Jacobs Consulting are the designers of the 375,000-square-foot lab mission taking form in Cambridge, Mass.
When finalized, the construction will rise 12 tales, together with two penthouse flooring. Tenants may have entry to a 5-acre park, three ranges of underground parking, a motorbike room and 5 out of doors terraces. With built-in good applied sciences, the constructing will purpose for LEED Gold and Wired Rating Platinum certifications.
The 43-acre Cambridge Crossing growth is slated to create 2.1 million sq. ft of business area, 2.4 million sq. ft of residential area, 100,000 sq. ft of eating and retail amenities, together with 11 acres of inexperienced area. The brand new district will provide direct entry to a number of transit choices, corresponding to MBTA’s Lechmere Inexperienced Line and the Neighborhood Faculty Orange Line. Present tenants embrace Bristol Myers Squibb, Philips, Sanofi and Cerevel Therapeutics.
With 1.9 million sq. ft already accomplished, the 4.5-million-square-foot Cambridge Crossing growth is considered one of Boston’s largest initiatives presently within the making. In keeping with Cushman & Wakefield’s newest Life Science Outlook, Boston leads the nation by way of under-construction lab area, with 13.9 million sq. ft taking form as of October. The pipeline’s completion will improve the metro’s present stock by an estimated 43 p.c.
